RNA Manufacturing Resources

1. Considerations And Strategies For Oligonucleotide Manufacturing Scale-Up 8/2/2023

   To keep up with oligonucleotide demand, manufacturing needs to shift toward larger-scale processes, but this scale-up process brings challenges that must be addressed.

2. Demand More From Your Oligo Synthesizer 3/4/2024

   The market for oligonucleotide therapeutics is expanding, and the pipeline is diverse. Gain insight into how you can fast-track your molecule's development with verified synthesizers, columns, and scientific support and expertise.

3. Improvement Of Self-Amplifying RNA Quality And Potency With IVT Optimization 1/28/2025

   Explore our study on optimizing In-Vitro Transcription (IVT) conditions for self-amplifying RNAs to achieve high yields, low residual dsRNA, and improved potency, and learn how these advancements can enhance RNA-based therapies.

4. Alternative To Cryobags For Large Volume Cryopreservation 6/6/2019

   This study demonstrates an optimized cooling protocol for cryopreserving large-volume cryovials in a controlled-rate freezer, avoiding the need for liquid nitrogen.

5. Reduce The Environmental Footprint Of Oligonucleotides 3/7/2023

   Industry experts answer attendees' questions from a recent webinar about sustainability concerns surrounding oligonucleotide manufacturing.

6. Scaling Personalized Medicines For Flexible Aseptic Filling 2/14/2024

   Traditional aseptic filling solutions can introduce contamination and variability. Learn about Cytiva's commitment to finding innovative solutions and improving patient outcomes in the field of medicine.

7. How Lipid Nanoparticles Enable Next-Gen Delivery 10/20/2025

   Cell therapy’s future depends on smarter gene delivery. Learn how lipid nanoparticles offer a scalable, cell-friendly alternative to electroporation and viral vectors for manufacturing efficiency.

8. Understanding The Microfluidic Platforms For Scaling Nanoparticle Production 10/13/2022

   Learn about the benefits of microfluidics for nanoparticle production over traditional methods as well as scaling nanoparticle production for clinical or industrial use.

9. GMP Manufacturing Facility For Viral Vector Production 3/27/2018

   A new GMP production facility for viral vectors from nonadherent cell cultures alleviates concerns that there will be a restriction of speed in getting viral vector products from the laboratory to the patient.

10. Eliminating Antibiotic Resistance Gene Transfer Risks In CGTs 8/14/2023

    Learn about the drawbacks of antibiotic resistance that can cause side effects in patients and how an antibiotic-free approach can ease the burden of regulatory compliance and accelerate development.